iSEND is an algorithmic model specific for advanced non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitors

被引：0
|
作者：
Park, Wungki [1 ]
Florou, Vaia [1 ]
Algaze, Sandra [1 ]
Saravia, Diana [1 ]
Kwon, Deukwoo [1 ,2 ]
Lopes, Gilberto [1 ]
机构：
[1] Univ Miami, Miami, FL USA
[2] Sylvester Comprehens Canc Ctr, Miami, FL USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2017年 / 5卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P75
引用
收藏
页数：1
相关论文
共 50 条
  • [41] PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement
    Isla, Dolores
    Sanchez, Alfredo
    Casal, Joaquin
    Cobo, Manuel
    Majem, Margarita
    Reguart, Noemi
    Zugazagoitia, Jon
    Bernabe, Reyes
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (15)
  • [42] Tumor mutational burden as a predictive biomarker for non-small cell lung cancer treated with immune checkpoint inhibitors of PD-1/PD-L1
    Shao, Min-min
    Xu, Yue-ping
    Zhang, Jin-jing
    Mao, Mao
    Wang, Meng-chuan
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (06): : 1446 - 1458
  • [43] Neoantigen Deletion Leads to Hyperprogressive Disease (HPD) in Non-Small Cell Lung Cancer (NSCLC) Treated with PD-1/PD-L1 Inhibitors
    Wu, D.
    Hong, X.
    Liu, Y.
    Zhang, K.
    Hu, Y.
    Gu, F.
    Liu, Y.
    Zhao, Z.
    Liu, J.
    Liu, L.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S934 - S934
  • [44] Real-world evidence and clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors
    Peng Song
    Jingcheng Zhang
    Congcong Shang
    Li Zhang
    Scientific Reports, 9
  • [45] Real-world evidenceand clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors
    Song, Peng
    Zhang, Jingcheng
    Shang, Congcong
    Zhang, Li
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [46] Risk Factors Analysis of AKI in Patients with Primary Non-small Cell Lung Cancer Treated with PD-1/PD-L1 Inhibitor
    Ying, Jiong-Ming
    Yan, Feng
    IRANIAN JOURNAL OF KIDNEY DISEASES, 2024, 18 (02) : 108 - 117
  • [47] Early Clinical Predictors of Progressive Disease or Non-Response to PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer
    Kumar, R.
    Brandao, M.
    Joharatnam, N.
    Pealing, J.
    Walder, D.
    Minchom, A.
    Milner-Watts, C.
    Moorcraft, S. Y.
    Turkes, F.
    Yousaf, N.
    Bhosle, J.
    Popat, S.
    O'Brien, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2147 - S2147
  • [48] Efficacy and safety of the PD-1/PD-L1 in metastasic non-small cell lung cancer (NSCLC)
    Gonzalez-Velez, Abel
    Pino-Villareal, Luis E.
    Barrera-Barinas, Alexander
    Castillo-Niuman, Andrea
    Tolosa-Perez, Erica N.
    Castelblanco, Diana, I
    Pinzon-Florez, Carlos E.
    Yomayusa, Nancy
    GACETA MEXICANA DE ONCOLOGIA, 2021, 20 (03): : 111 - 123
  • [49] PD-L1 expression and EGFR status in advanced non-small-cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis
    Li, Jing
    Gu, Jian
    FUTURE ONCOLOGY, 2019, 15 (14) : 1667 - 1678
  • [50] Determinants of survival in advanced non-small cell lung cancer patients treated with anti-PD-1/PD-L1 therapy
    Ali, Wael Abdullah Sultan
    Hui, Pan
    Ma, Yuxiang
    Wu, Yuehan
    Zhang, Yang
    Chen, Yukun
    Hong, Shaodong
    Yang, Yunpeng
    Huang, Yan
    Zhao, Yuanyuan
    Fang, Wenfeng
    Zhao, Hongyun
    Zhang, Li
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (22)
12345